vs
Side-by-side financial comparison of BeOne Medicines Ltd. (ONC) and RENAISSANCERE HOLDINGS LTD (RNR). Click either name above to swap in a different company.
RENAISSANCERE HOLDINGS LTD is the larger business by last-quarter revenue ($2.2B vs $1.5B, roughly 1.5× BeOne Medicines Ltd.). RENAISSANCERE HOLDINGS LTD runs the higher net margin — 23.5% vs 4.4%, a 19.1% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs -36.8%). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs -11.9%).
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
RenaissanceRe Holdings Ltd is a Bermudian provider of reinsurance, insurance and other related business services. The company operates in reinsurance, insurance and ventures.
ONC vs RNR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $2.2B |
| Net Profit | $66.5M | $515.8M |
| Gross Margin | 90.5% | — |
| Operating Margin | 12.4% | — |
| Net Margin | 4.4% | 23.5% |
| Revenue YoY | 32.8% | -36.8% |
| Net Profit YoY | 143.8% | 72.6% |
| EPS (diluted) | $0.05 | $6.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.2B | ||
| Q4 25 | $1.5B | $3.0B | ||
| Q3 25 | $1.4B | $3.2B | ||
| Q2 25 | $1.3B | $3.2B | ||
| Q1 25 | $1.1B | $3.5B | ||
| Q4 24 | $1.1B | $2.3B | ||
| Q3 24 | $1.0B | $4.0B | ||
| Q2 24 | $929.2M | $2.8B |
| Q1 26 | — | $515.8M | ||
| Q4 25 | $66.5M | $760.5M | ||
| Q3 25 | $124.8M | $916.5M | ||
| Q2 25 | $94.3M | $835.4M | ||
| Q1 25 | $1.3M | $170.0M | ||
| Q4 24 | $-151.9M | $-189.7M | ||
| Q3 24 | $-121.3M | $1.2B | ||
| Q2 24 | $-120.4M | $503.9M |
| Q1 26 | — | — | ||
| Q4 25 | 90.5% | — | ||
| Q3 25 | 86.1% | — | ||
| Q2 25 | 87.5% | — | ||
| Q1 25 | 85.2% | — | ||
| Q4 24 | 85.8% | — | ||
| Q3 24 | 83.0% | — | ||
| Q2 24 | 85.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 12.4% | 42.5% | ||
| Q3 25 | 11.5% | 46.3% | ||
| Q2 25 | 6.7% | 41.8% | ||
| Q1 25 | 1.0% | -2.0% | ||
| Q4 24 | -7.0% | -3.6% | ||
| Q3 24 | -12.0% | 43.7% | ||
| Q2 24 | -11.5% | 25.0% |
| Q1 26 | — | 23.5% | ||
| Q4 25 | 4.4% | 25.6% | ||
| Q3 25 | 8.8% | 28.7% | ||
| Q2 25 | 7.2% | 26.1% | ||
| Q1 25 | 0.1% | 4.9% | ||
| Q4 24 | -13.5% | -8.3% | ||
| Q3 24 | -12.1% | 29.8% | ||
| Q2 24 | -13.0% | 17.8% |
| Q1 26 | — | $6.57 | ||
| Q4 25 | $0.05 | $16.16 | ||
| Q3 25 | $0.08 | $19.40 | ||
| Q2 25 | $0.06 | $17.20 | ||
| Q1 25 | $0.00 | $3.27 | ||
| Q4 24 | $-0.10 | $-3.76 | ||
| Q3 24 | $-0.09 | $22.62 | ||
| Q2 24 | $-0.09 | $9.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.5B | $1.6B |
| Total DebtLower is stronger | $836.4M | — |
| Stockholders' EquityBook value | $4.4B | $4.3B |
| Total Assets | $8.2B | $53.7B |
| Debt / EquityLower = less leverage | 0.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.6B | ||
| Q4 25 | $4.5B | $1.7B | ||
| Q3 25 | $4.0B | $1.7B | ||
| Q2 25 | $2.8B | $1.4B | ||
| Q1 25 | $2.5B | $1.6B | ||
| Q4 24 | $2.6B | $1.7B | ||
| Q3 24 | $2.7B | $1.6B | ||
| Q2 24 | $2.6B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $836.4M | $2.3B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $2.0B |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $4.4B | $11.6B | ||
| Q3 25 | $4.1B | $11.5B | ||
| Q2 25 | $3.8B | $10.8B | ||
| Q1 25 | $3.5B | $10.3B | ||
| Q4 24 | $3.3B | $10.6B | ||
| Q3 24 | $3.4B | $11.2B | ||
| Q2 24 | $3.4B | $10.2B |
| Q1 26 | — | $53.7B | ||
| Q4 25 | $8.2B | $53.8B | ||
| Q3 25 | $7.6B | $54.5B | ||
| Q2 25 | $6.3B | $54.7B | ||
| Q1 25 | $5.8B | $53.6B | ||
| Q4 24 | $5.9B | $50.7B | ||
| Q3 24 | $5.8B | $52.8B | ||
| Q2 24 | $5.7B | $51.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.19× | 0.20× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.17× | ||
| Q2 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $417.3M | — |
| Free Cash FlowOCF − Capex | $379.8M | — |
| FCF MarginFCF / Revenue | 25.4% | — |
| Capex IntensityCapex / Revenue | 2.5% | — |
| Cash ConversionOCF / Net Profit | 6.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $941.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $417.3M | $483.0M | ||
| Q3 25 | $402.6M | $1.6B | ||
| Q2 25 | $263.6M | $1.5B | ||
| Q1 25 | $44.1M | $157.8M | ||
| Q4 24 | $75.2M | $778.9M | ||
| Q3 24 | $188.4M | $1.5B | ||
| Q2 24 | $-95.6M | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | $379.8M | — | ||
| Q3 25 | $354.5M | — | ||
| Q2 25 | $219.8M | — | ||
| Q1 25 | $-12.3M | — | ||
| Q4 24 | $-17.3M | — | ||
| Q3 24 | $54.7M | — | ||
| Q2 24 | $-205.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | 25.4% | — | ||
| Q3 25 | 25.1% | — | ||
| Q2 25 | 16.7% | — | ||
| Q1 25 | -1.1% | — | ||
| Q4 24 | -1.5% | — | ||
| Q3 24 | 5.5% | — | ||
| Q2 24 | -22.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | 8.2% | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | 11.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.28× | 0.64× | ||
| Q3 25 | 3.22× | 1.73× | ||
| Q2 25 | 2.79× | 1.76× | ||
| Q1 25 | 34.71× | 0.93× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 2.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
